The company said it plans to produce 20 crore doses of Covaxin per annum in the GMP facilities that are already operational
Government of India had approved the use of Covaxin as part of the vaccination drive as one under a clinical trial mode . This, it was learnt, was causing concern among potential recipients of this particular vaccine among some healthcare personnel in the state. (Representational Photo)
Hyderabad: Bharat Biotech has decided to boost its vaccine manufacturing capacity for Covaxin by adding yet another production line at its Ankleshwar-based subsidiary, Chiron Behring Vaccines. The company has already been producing its Covid-19 vaccine at its Hyderabad and Bengaluru facilities.
The company said it plans to produce 20 crore doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines.
The product availability at Ankleshwar, the company said, will commence from October 2021.
The additional manufacturing at Chiron Behring would effectively take the volumes up to 100 crore doses per annum, with its own established campuses.
( Source : Deccan Chronicle. )
Next Story
